Francis A. Farraye, MD
Adjunct Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Gastroenterology

MD, Albert Einstein College of Medicine
MSc, Harvard School of Public Health
BS, Stony Brook University



Dr. Farraye is a Senior Associate Consultant in the Section of Gastroenterology and Hepatology at the Mayo Clinic in Jacksonville Florida where he co-directs the Inflammatory Bowel Disease Center. Prior to relocating in 2019, he was Clinical Director in the Section of Gastroenterology and the Inflammatory Bowel Disease Center at Boston Medical Center. At Chobanian and Avedisian School of Medicine, he was Professor of Medicine. Dr. Farraye earned his medical doctorate from the Albert Einstein College of Medicine in New York and his master's degree in Epidemiology from the Harvard School of Public Health.

Dr. Farraye's clinical interests are in the care of patients with inflammatory bowel disease. He is currently investigating C. difficile infection in IBD patients, the management and diagnosis of dysplasia and cancer in patients with IBD; social media use and health literacy in IBD patients; hepatitis B vaccination efficacy in patients with IBD; and subclinical hepatic fibrosis in patients with IBD.

A frequent speaker and invited lecturer on topics on the diagnosis and management of inflammatory bowel disease, Dr. Farraye has authored or co-authored over 450 original scientific manuscripts, book chapters, reviews, and abstracts. He is the series editor for the text Curbside Consultations in Gastroenterology and co-edited the text, Curbside Consultation in Inflammatory Bowel Disease and Gastrointestinal Emergencies. His books for patients include Questions and Answers about Ulcerative Colitis, Questions and Answers about Crohn's Disease and Ulcerative Colitis for Dummies.

Dr. Farraye is a Fellow of the American Society of Gastrointestinal Endoscopy, American Gastroenterological Association and the American College of Gastroenterology. He has served on numerous national and international committees including as a member of the ACG Board of Trustees. He is co-chair of the Crohn's and Colitis Foundation Membership Committee and a member of the Chapter Medical Advisory Committee for the New England Crohn's and Colitis Foundation and a past chairman. The New England Crohn's and Colitis Foundation named Dr. Farraye Humanitarian of the Year in 2003. In 2009, the ACG awarded Dr. Farraye the William Carey Award for service to the college. Dr. Farraye has been recognized as "Top Doctor" in Gastroenterology by Boston Magazine and U.S. News and World Report since 2010.

Member
Boston University
Center for Regenerative Medicine


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




A Phase III, Open-Label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn's Disease
04/01/2009 - 09/30/2017 (PI)
Millennium Pharmaceuticals, Inc.


PUCCINI-Prospective Cohort of Ulcerative Colitis and Crohn's Disease Patients Undergoing Surgery to Identify Risk Factors for Post-Operative Infection I
06/23/2014 - 07/01/2017 (Subcontract PI)
Icahn School of Medicine at Mount Sinai Crohns & Colitis Fdn


A Study to Assess the Association of Clinical outcome with serum drug concentration levels and anti-drug antibody in moderately to severely active Crohn's Disease patients treated with Adalimumab prot
08/01/2011 - 07/31/2012 (PI)
Prometheus Laboratories, Inc.


PROCUREMENT OF BLOOD SAMPLES FROM IBD, GI CONTROLS AND HEALTHY VOLUN TEER SUBJECTS FOR USE IN THE
01/01/2011 - 12/31/2011 (PI)
Prometheus Laboratories, Inc.


C13006, A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study for the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Modera
04/01/2009 - 05/31/2011 (PI)
Millennium Pharmaceuticals, Inc.


C13007, A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study for the Induction and Maintenance of Clinical Response and Remission by Vedolizuamb (MLN0002) in Patients with Modera
04/01/2009 - 05/31/2011 (PI)
Millennium Pharmaceuticals, Inc.


A Phase IIIb Multi-Center, Double-Blind, Placebo-Controlled, Randomized Trial to Examine the Corticosteroid-Sparing Effects of Certolizumab Pegol in Patients with Moderate to Severe Crohn’s Disease (COSPAR I)
11/06/2006 - 11/05/2008 (PI)
UCB Pharma, Inc.

A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severe Crohn’s Disease with Previous Exposure to Infliximab
12/08/2006 - 06/07/2007 (PI)
Abbott Laboratories

A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate for the Induction of Clinical Response in Patients with Crohn’s Disease
10/06/2005 - 10/05/2006 (PI)
Synta Pharmaceuticals Corporation

An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects with Irritable Bowel Syndrome
11/04/2004 - 07/19/2005 (PI)
GlaxoSmithKline, Inc.

Showing 10 of 14 results. Show All Results

Entyvio (velolizumab) long-term safety study
04/12/2016 - 06/30/2023 (Multi-PI)
PI: Francis A. Farraye, MD
Takeda Pharmaceuticals

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Invest to Invest…
10/03/2016 - 10/02/2019 (PI)
Celgene Corporation

EH-5151- Evaluating the Nutritional Impact of Serum-Derived Bovine Immunoglobulin / Protein Isola…
07/25/2016 - 07/24/2019 (PI)
Entera Health, Inc.

IBD-600 Registry
09/19/2018 - 03/31/2019 (PI)
Corrona, LLC

An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Ac…
10/08/2015 - 09/30/2018 (PI)
Takeda Pharmaceuticals

Sample Collection Study to Evaluate DNA Markers in Subjects with Inflammatory Bowel Disease (IBD)…
12/22/2014 - 10/10/2017 (PI)
Exact Sciences

Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease:OCEANIA Study
12/12/2014 - 06/30/2017 (PI)
Exact Sciences

A Prospective, Randomized,Double Blinded, Placebo-Controlled Phase II Clinical Study of Trichuris…
05/01/2014 - 12/31/2015 (PI)
Duke University NIH-NIAID

Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease
12/20/2012 - 09/01/2015 (PI)
Cubist Pharmaceuticals Inc

Methotrexate Response in Treatment of UC - MERIT-UC
08/15/2011 - 01/31/2014 (PI)
University of North Carolina NIH-NIDDK

Showing 10 of 13 results. Show All Results

Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Desai A, Hashash JG, Kochhar GS, Hayney MS, Caldera F, Farraye FA. Recombinant Zoster Vaccine [RZV] is Effective in Patients with Inflammatory Bowel Disease: A US Propensity Matched Cohort Study. J Crohns Colitis. 2024 Jun 03; 18(6):828-835. PMID: 38224526
     
  2. Karime C, Farraye FA, Hashash JG. Use of Immune Checkpoint Inhibitors in Patients With Inflammatory Bowel Disease After Ileal Pouch-Anal Anastomosis. Inflamm Bowel Dis. 2024 Apr 03; 30(4):681-685. PMID: 37260345
     
  3. Caldera F, Rolak S, Farraye FA, Necela BM, Cogen D, Zona EE, Schell TL, Ramirez OR, Almasry M, Chun K, Hayney MS, Knutson KL. Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy. Clin Transl Gastroenterol. 2024 Apr 01; 15(4):e00688. PMID: 38349178; PMCID: PMC11042770; DOI: 10.14309/ctg.0000000000000688;
     
  4. Hashash JG, Yu Ci Ng F, Farraye FA, Wang Y, Colucci DR, Baxi S, Muneer S, Reddan M, Shingru P, Melmed GY. Inter- and Intraobserver Variability on Endoscopic Scoring Systems in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2024 Mar 28. PMID: 38547325
     
  5. Smith RA, Desai A, Barnes EL, Hayney M, Kochhar GS, Hashash JG, Farraye FA, Caldera F. Patients With Inflammatory Bowel Disease Are at Increased Risk of Hospitalization Due to Respiratory Syncytial Virus. Am J Gastroenterol. 2024 Mar 21. PMID: 38318981
     
  6. Brenner EJ, Weaver KN, Zhang X, Kastl AJ, Strople JA, Adler J, Dubinsky MC, Bousvaros A, Watkins R, Dai X, Chen W, Cross RK, Higgins PDR, Ungaro RC, Bewtra M, Bellaguarda EA, Farraye FA, Chun KY, Zikry M, Bastidas M, Firestine A, Craig RG, Boccieri ME, Long MD, Kappelman MD. Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2024 Feb 17. PMID: 38369224
     
  7. Kastl AJ, Weaver KN, Zhang X, Strople JA, Adler J, Kelsen JR, Dubinsky MC, Bousvaros A, Watkins R, Dai C, Cross RK, Higgins PDR, Ungaro R, Bewtra M, Bellaguarda EA, Farraye FA, Chun K, Zikry M, Bastidas M, Boccieri ME, Firestine A, Long MD, Kappelman MD. Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2024 Apr; 78(4):871-877. PMID: 38356293
     
  8. Odah T, Karime C, Hashash JG, Farraye FA. Nintedanib-Induced Colitis Can Mimic Inflammatory Bowel Disease. ACG Case Rep J. 2024 Feb; 11(2):e01282. PMID: 38333722; PMCID: PMC10852397; DOI: 10.14309/crj.0000000000001282;
     
  9. Karime C, Crosby S, Bhat S, Hashash JG, Farraye FA. Rapid Adoption of Pneumococcal 20-Valent Conjugate Vaccination in Adult Patients With Inflammatory Bowel Disease: An Analysis One Year After Availability. J Clin Gastroenterol. 2024 Feb 01; 58(2):207-209. PMID: 38047595
     
  10. Farraye FA. Reviewing Recommendations for Vaccines and Health Care Maintenance in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2024 Feb; 20(2):115-118. PMID: 38414913; PMCID: PMC10895912
     
Showing 10 of 474 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 472 publications over 36 distinct years, with a maximum of 39 publications in 2021 and 2023

YearPublications
19871
19883
19892
19901
19912
19921
19944
19964
19972
19983
19998
20005
20018
200211
200314
200415
200514
200614
20076
200818
200916
201026
201120
20129
201323
201417
201517
201624
201719
201810
201917
202018
202139
202229
202339
202413

2017 American College of Gastroenterology: Presidential Poster Award
2014 Robert Dawson Evans Award for Quality Improvement and Patient Safety: Committee Member
2013 Institute for Health Care Improvement: Boston University Faculty Development Award: Quality Improvement for Department Chiefs
2013 Boston University School of Medicine: Research Mentor of the Year
2012 Richard Farmer Honorary Lecture: Health Care Maintenance in the IBD Patient
2011 U.S. News and World Report: Top Doctor
2010 Boston Magazine: Best of Boston, Gastroenterology
2010 Boston University School of Management: Boston University Faculty Development Award: Pocket MBA for Physicians
2009 American College of Gastroenterology: William Carey Award
2003 American College of Gastroenterology: Board of Governors Achievement Award
2003 New England Crohn’s and Colitis Foundation of America: Humanitarian of the Year
2002 American College of Gastroenterology: Presidential Poster Award
1999 Harvard Community Health Plan: Key Contribution Award
1998 Harvard Pilgrim Health Care: Ebert Fellowship
1995 Harvard Community Health Plan: Key Contribution Award
1993 Harvard Community Health Plan: Key Contribution Award
1990 Harvard Community Health Plan: Peer Recognition Award
1990 Harvard Community Health Plan: Diamond Award
1990 Harvard Community Health Plan: Key Contribution Award
1986 Harvard Community Health Plan: Peer Recognition Award
1979 American Liver Foundation: Research Fellowship
1979 American Gastroenterological Association: Research Fellowship
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Colon Cancer
Colon Polyps
Crohn’s Disease
Dysplasia
Ileal Pouch Anal Anastomosis
Inflammatory Bowel Disease
Ulcerative Colitis
Vitamin D

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

85 E. Concord St
Boston MA 02118
Google Map


Farraye's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department